Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware, 19716.
Biotechnol Bioeng. 2014 May;111(5):904-12. doi: 10.1002/bit.25158. Epub 2013 Dec 11.
Downstream processing of monoclonal antibodies (mAbs) has evolved to allow the specific process for a new product to be developed largely by empirical specialization of a platform process that enables removal of impurities of different kinds. A more complete characterization of impurities and the product itself would provide insights into the rational design of efficient downstream processes. This work identifies and characterizes host cell protein (HCP) product-associated impurities, that is, HCP species carried through the downstream processes via direct interactions with the mAb. Interactions between HCPs and mAbs are characterized using cross-interaction chromatography under solution conditions typical of those used in downstream processing. The interacting species are then identified by two-dimensional gel electrophoresis and mass spectrometry. This methodology has been applied to identify product-associated impurities in one particular purification step, namely protein A affinity chromatography, for four therapeutic mAbs as well as the Fab and Fc domains of one of these mAbs. The results show both the differences in HCP-mAb interactions among different mAbs, and the relative importance of product association compared to co-elution in protein A affinity chromatography.
单克隆抗体(mAbs)的下游处理已经发展到可以通过经验专业化平台工艺来开发新产品的特定工艺,该平台工艺能够去除不同类型的杂质。更全面地了解杂质和产品本身将有助于合理设计高效的下游工艺。这项工作确定并表征了宿主细胞蛋白(HCP)与产品相关的杂质,即通过与 mAb 的直接相互作用,通过下游工艺携带的 HCP 物种。使用与下游处理中使用的条件典型的溶液条件下的互作色谱法来表征 HCP 与 mAb 之间的相互作用。然后通过二维凝胶电泳和质谱法鉴定相互作用的物质。该方法已应用于鉴定四种治疗性 mAb 以及其中一种 mAb 的 Fab 和 Fc 结构域在一个特定的纯化步骤(即蛋白 A 亲和层析)中与产品相关的杂质。结果表明,不同 mAb 之间 HCP-mAb 相互作用存在差异,并且与蛋白 A 亲和层析中的共洗脱相比,产品相关性的相对重要性。